Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
Status
Conditions
Treatments
Details and patient eligibility
About
This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Full description
The purpose of this pilot study is to explore the association between personality and adherence to a specific type of oral cancer medication - tyrosine kinase inhibitor (TKI) - in patients with chronic myeloid leukemia (CML). 75 individuals with chronic phase CML who are being treated with TKIs will be recruited. Consenting patients will participate in a focused interview where TKI adherence, personality type, and quality of life and symptom burden will be assessed using validated questionnaires. Information on treatment response and the treating physician's perception of TKI adherence will be obtained from the electronic health record.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- 18 years of age or older
- Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
- Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
- A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
- A member of a patient support group organized by the CML Buster Foundation
- Do not meet any of the criteria listed under "Exclusion Requirements"
Exclusion criteria
- Unable to read and speak English
- Impaired decisional capacity to consent
Trial design
75 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
University of California Irvine Medical; Chao Family Comprehensive Cancer Center University of California, Irvine
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal